Azithromycin Dosage Recommendations
For healthy adults, azithromycin is dosed at 500 mg on day 1, followed by 250 mg daily on days 2-5 for most infections; for children ≥15 kg, use 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg daily (max 250 mg) on days 2-5; for infants <15 kg, use 10 mg/kg daily for 5 days; no dose adjustment is needed in severe renal impairment (caution advised), and no specific adjustment can be recommended for hepatic impairment due to lack of data. 1
Adult Dosing
Standard Regimens
The FDA-approved dosing varies by indication 1:
- Most respiratory infections (community-acquired pneumonia, pharyngitis/tonsillitis, skin/soft tissue infections): 500 mg as single dose on Day 1, followed by 250 mg once daily on Days 2-5
- Acute bacterial exacerbations of COPD: Either 500 mg daily × 3 days OR the standard 5-day regimen above
- Acute bacterial sinusitis: 500 mg daily × 3 days
- Genital ulcer disease (chancroid): Single 1 gram dose
- Non-gonococcal urethritis/cervicitis: Single 1 gram dose
- Gonococcal urethritis/cervicitis: Single 2 gram dose
Azithromycin can be taken with or without food, though food decreases bioavailability by approximately 50% 2.
Pediatric Dosing (≥15 kg)
Weight-Based Approach
For children weighing ≥15 kg, the standard regimen follows a 5-day course 1:
- Day 1: 10 mg/kg (maximum 500 mg)
- Days 2-5: 5 mg/kg daily (maximum 250 mg per day)
Specific Indications in Children ≥15 kg
Acute otitis media has three approved regimens 1:
- 5-day regimen: 10 mg/kg day 1, then 5 mg/kg days 2-5
- 3-day regimen: 10 mg/kg daily × 3 days
- 1-day regimen: 30 mg/kg as single dose
Community-acquired pneumonia: 10 mg/kg day 1, then 5 mg/kg days 2-5 1
Pharyngitis/tonsillitis: 12 mg/kg daily × 5 days (higher dose needed due to recurrence rates with standard dosing) 1, 3
Acute bacterial sinusitis: 10 mg/kg daily × 3 days 1
Important Caveat for Streptococcal Pharyngitis
Research demonstrates that higher cumulative doses (60 mg/kg total) are significantly more effective than lower doses (30 mg/kg total) for group A streptococcal pharyngitis, with bacterial failure occurring 3 times more frequently at lower doses 3. This is why the FDA label recommends 12 mg/kg daily × 5 days for this indication.
Pediatric Dosing (<15 kg)
For infants and young children <15 kg, dosing depends on the indication 4, 1:
Pertussis Treatment/Prophylaxis
- Infants <6 months: 10 mg/kg daily × 5 days 4
- Infants ≥6 months but <15 kg: 10 mg/kg day 1 (max 500 mg), then 5 mg/kg daily days 2-5 (max 250 mg) 4
Other Infections in Children <15 kg
For acute otitis media and other respiratory infections, the same weight-based dosing applies as above, with specific volumes provided in the FDA label based on suspension concentration 1.
Critical safety note: Azithromycin is preferred over erythromycin in infants <1 month due to lower risk of infantile hypertrophic pyloric stenosis (IHPS), though infants receiving any macrolide should be monitored for this complication 4.
Renal Impairment
No dosage adjustment is required for patients with renal impairment, including severe impairment (GFR <10 mL/min). 1, 5
The pharmacokinetic data are reassuring:
- In mild-to-moderate renal impairment (GFR 10-80 mL/min): AUC increased only 4.2% and Cmax increased 5.1% compared to normal renal function 1
- In severe renal impairment (GFR <10 mL/min): AUC increased 35% and Cmax increased 61% 1
Despite the modest increase in exposure with severe renal impairment, the FDA label states "caution should be exercised" but does not recommend dose reduction 1. This is because azithromycin is primarily eliminated via biliary excretion (approximately 6% appears unchanged in urine), and the extensive tissue distribution means plasma concentrations remain low even with reduced renal clearance 2, 5.
Practical approach: Use standard doses even in severe renal impairment, but monitor more closely for adverse effects, particularly gastrointestinal symptoms and QTc prolongation.
Hepatic Impairment
No dose adjustment recommendations can be made for hepatic impairment because pharmacokinetic studies have not been performed in this population. 1
The FDA label advises that azithromycin "should be prescribed with caution to patients with impaired hepatic function" 4. Given that biliary excretion is the major elimination route, theoretical concerns exist about accumulation in severe hepatic disease.
Practical approach: In mild-to-moderate hepatic impairment, use standard doses with clinical monitoring. In severe hepatic impairment, consider alternative antibiotics if possible, or use azithromycin with enhanced monitoring for adverse effects if no suitable alternative exists.
Special Populations
Elderly Patients
No dosage adjustment based on age alone 1. However, elderly women may experience 30-50% higher peak concentrations without significant accumulation 1. Standard adult dosing applies.
Pregnancy
Azithromycin is FDA Pregnancy Category B 4. Standard dosing applies when indicated.
Intravenous Administration
For pediatric patients requiring IV therapy (e.g., severe pneumonia, inability to take oral medications):
- Dose: 10 mg/kg daily (maximum 500 mg) 6, 7
- Administration: Infuse over 1 hour
- Transition: Switch to oral therapy when clinically appropriate
Pharmacokinetic studies show comparable disposition across pediatric age groups (0.5-16 years) with IV dosing 7.
Common Pitfalls to Avoid
Underdosing streptococcal pharyngitis: Use 12 mg/kg daily × 5 days, not the standard 10 mg/kg/5 mg/kg regimen, to prevent treatment failure 3
Unnecessary dose reduction in renal impairment: Unlike aminoglycosides, azithromycin does not require dose adjustment even in severe renal disease 1, 5
Food timing confusion: While food decreases absorption, this is not clinically significant enough to mandate fasting administration for most indications 2
Overlooking drug interactions: Monitor patients on medications metabolized by cytochrome P450 (digoxin, triazolam, ergot alkaloids) and avoid concurrent aluminum/magnesium antacids 4
QTc prolongation risk: Particularly relevant in elderly patients, those with cardiac disease, or concurrent QT-prolonging medications—obtain baseline ECG in high-risk patients